Cited 0 times in
High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, HW | - |
dc.contributor.author | Hwang, YH | - |
dc.contributor.author | Han, JH | - |
dc.contributor.author | Choi, JH | - |
dc.contributor.author | Kang, SY | - |
dc.contributor.author | Jeong, SH | - |
dc.contributor.author | Ann, MS | - |
dc.contributor.author | Oh, YT | - |
dc.contributor.author | Kim, JH | - |
dc.contributor.author | Kim, CH | - |
dc.contributor.author | Sheen, SS | - |
dc.date.accessioned | 2011-05-16T06:33:28Z | - |
dc.date.available | 2011-05-16T06:33:28Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1368-8375 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/2608 | - |
dc.description.abstract | We evaluated the prognostic significance of excision repair cross-complementation group 1 protein (ERCC1) and thymidylate synthase (TS) in patients with nasopharyngeal cancer (NPC) treated with concurrent chemoradiotherapy (CCRT). Pre-treatment tumor biopsy specimens from 41 patients with locally advanced NPC (stage I: 1, II: 10, III: 9, IV: 21 patients) were analyzed for ERCC1 and TS expression by immunohistochemistry. All patients were treated with one cycle of induction chemotherapy (5-fluorouracil 1000 mg/m(2)/day and cisplatin 20mg/m(2)/day, days 1-4) followed by CCRT starting on day 22. CCRT consisted of radiotherapy (70 Gy/35 fractions for 7 weeks) with cisplatin 20mg/m(2)/day for 4 days on weeks 1, 4, and 7 of radiotherapy. High expression of ERCC1 and TS was observed in 25 (60%) and 21 (51%) patients, respectively. High expression of ERCC1 was associated with WHO type 1 or 2 histology (p=0.045). With a median follow-up duration of 106 months (32-152 months) in survivors, the 5-year overall survival (OS) of all patients was 53%. In univariate analysis, 5-year OS (73% versus 39%, p=0.005) was significantly inferior in patients with high expression of ERCC1, while high expression of TS was not correlated with patient outcome. In multivariate analysis, high expression of ERCC1 was a significant independent prognostic factor for poor OS (p=0.029) along with WHO type 1 or 2 histology. High expression of ERCC1 protein may be a useful prognostic factor for poor outcome in patients with locally advanced NPC treated with CCRT. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Asia, Southeastern | - |
dc.subject.MESH | DNA-Binding Proteins | - |
dc.subject.MESH | Endonucleases | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nasopharyngeal Neoplasms | - |
dc.subject.MESH | Neoplasm Proteins | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Thymidylate Synthase | - |
dc.subject.MESH | Young Adult | - |
dc.title | High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. | - |
dc.type | Article | - |
dc.identifier.pmid | 20153243 | - |
dc.identifier.url | http://linkinghub.elsevier.com/retrieve/pii/S1368-8375(09)01012-4 | - |
dc.contributor.affiliatedAuthor | 이, 현우 | - |
dc.contributor.affiliatedAuthor | 한, 재호 | - |
dc.contributor.affiliatedAuthor | 최, 진혁 | - |
dc.contributor.affiliatedAuthor | 강, 석윤 | - |
dc.contributor.affiliatedAuthor | 정, 성현 | - |
dc.contributor.affiliatedAuthor | 안, 미선 | - |
dc.contributor.affiliatedAuthor | 오, 영택 | - |
dc.contributor.affiliatedAuthor | 김, 장희 | - |
dc.contributor.affiliatedAuthor | 김, 철호 | - |
dc.contributor.affiliatedAuthor | 신, 승수 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1016/j.oraloncology.2009.12.007 | - |
dc.citation.title | Oral oncology | - |
dc.citation.volume | 46 | - |
dc.citation.number | 3 | - |
dc.citation.date | 2010 | - |
dc.citation.startPage | 209 | - |
dc.citation.endPage | 213 | - |
dc.identifier.bibliographicCitation | Oral oncology, 46(3). : 209-213, 2010 | - |
dc.identifier.eissn | 1879-0593 | - |
dc.relation.journalid | J013688375 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.